Drug Trial Radar · NCT01607476
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)
Last checked: Nov 20, 2026Latest source record: Apr 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Jul 2012
Primary completion
Dec 2014
Study completion Mar 2016
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 30, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The intent of this research protocol is to test the equivalency of two amyloid imaging drugs (C11 Pittsburgh Compound B and F18 Flutemetamol). The investigators hypothesize that there will be no significant difference in the distribution of the agents to areas of amyloid deposition in the brain or to other normal brain structures. Recent data have shown similarity in the distribution of the drugs in subjects with Alzheimer's disease (AD) or mild cognitive impairment (MCI). No comparison data of the two PET drugs in normal subjects has been published. It is important to understand differences in the images and biodistribution from the two drugs in normal subjects as nonspecific accumulation of the drugs in brain structures such as white matter appear to differ slightly and could affect image performance.
Conditions
- Alzheimer's Disease
Interventions
C11 PiBDrug
One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
F18 FlutametamolDrug
One time intravenous administration of 3-7 mCi F18 Flutametamol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global Distribution of C11 PiB in the BrainTime frame: Approximately one hour after injection of positron emission tomography (PET) drug
- Global Distribution of F18 Flutemetamol in the BrainTime frame: Approximately one hour after injection of positron emission tomography (PET) drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.